Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral...
Vous n'êtes pas connecté
SEOUL, South Korea, July 11, 2024. ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be 'prostate cancer patients...
Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral...
Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral...
During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are necessary.
) The text version of this document is not available. You can access...
) The text version of this document is not available. You can access...
Many men with aggressive medlinkprostate cancer/medlink often face a high risk of the disease returning even after treatment. A recent Phase 2...
Many men with aggressive medlinkprostate cancer/medlink often face a high risk of the disease returning even after treatment. A recent Phase 2...
Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the...
Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the...
A dual-protective approach using botulinum toxin (Botox) alongside an anti-nausea patch significantly reduces salivary gland toxicity in patients with...